ReviewNeuropsychiatric disease and treatment2013
Treatment of neurolept-induced tardive dyskinesia.
Review in Neuropsychiatric disease and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.Drug design, development and therapy · 2018Pooled it
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Neurology · 2017Trial
- Reporting Frequency of Antipsychotics-Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan.Neuropsychopharmacology reports · 2025Article
- A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.Neuropsychopharmacology reports · 2024Article
- Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.Neuropsychiatric disease and treatment · 2021Review
- Neurobiological mechanisms associated with antipsychotic drug-induced dystonia.Journal of psychopharmacology (Oxford, England) · 2021Review
- Tardive Dyskinesia: Treatment Update.Current neurology and neuroscience reports · 2019Review
- Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.Journal of managed care & specialty pharmacy · 2019Article
- Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Review
- Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States.PloS one · 2019Observational
- Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.Neurology and therapy · 2018Review
- Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2018Article
- Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis.Shanghai archives of psychiatry · 2017Article
- Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.Experimental neurology · 2016Article
- A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia.Journal of clinical psychopharmacology · 2015Article
- Temporomandibular disorders in patients with schizophrenia using antipsychotic agents: a discussion paper.Drug, healthcare and patient safety · 2014Review
- Divalproex sodium leading to sustained significant improvement in tardive dyskinesia in a patient with bipolar disorder.Indian journal of psychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tardive dyskinesia (TDK) includes orobuccolingual movements and "piano-playing" movements of the limbs. It is a movement disorder of delayed onset that can occur in the setting of neuroleptic treatment as well as in other diseases and following treatment with other drugs. The specific pathophysiology resulting in TDK is still not completely understood but possible mechanisms include postsynaptic dopamine receptor hypersensitivity, abnormalities of striatal gamma-aminobutyric acid (GABA) neurons, and degeneration of striatal cholinergic interneurons. More recently, the theory of synaptic plasticity has been proposed. Considering these proposed mechanisms of disease, therapeutic interventions have attempted to manipulate dopamine, GABA, acetylcholine, norepinephrine and serotonin pathways and receptors. The data for the effectiveness of each class of drugs and the side effects were considered in turn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.